Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
about
Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancersDevelopment of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysisThe adverse effects of sorafenib in patients with advanced cancers.Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations.Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-AnalysisTargeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report.Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.Hypertension in malignancy-an underappreciated problem.
P2860
Q26801289-783605FC-A91B-416C-8C04-99F87B5238CEQ30240748-DCD25D88-D120-433C-9906-36C030B4C5FCQ30249335-5BB8BB59-3CBD-487D-8BAD-F56A6776A411Q36024704-94097102-E227-49ED-961D-6FFBA7C227D6Q38286308-84253F30-B38A-446F-AB0E-5536FCB6D889Q38503419-931BF6C5-898A-425A-9026-7AFBD8770820Q38527941-11525759-F9BD-482D-BC7F-0FC3B0EFF35FQ38626515-FE9D29D0-614F-45A2-903B-C59A548E7D60Q38652294-1D68B11E-0CE8-4F2D-B744-FB01367890A1Q42980163-63A3AF0E-D49F-401A-8730-0C161261F941Q47594620-6D179EEF-26EB-4CC7-A566-118700A03FFAQ48166586-3934607E-AD18-45A5-9242-18D1AD3AF5DFQ54959206-F6E78842-B532-4910-ACCF-71D3988EB9F8Q55071881-A905A932-0DCD-4564-A194-6F42570F70AF
P2860
Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Risk of cardiovascular toxicit ...... atic review and meta-analysis.
@en
type
label
Risk of cardiovascular toxicit ...... atic review and meta-analysis.
@en
prefLabel
Risk of cardiovascular toxicit ...... atic review and meta-analysis.
@en
P2860
P356
P1433
P1476
Risk of cardiovascular toxicit ...... matic review and meta-analysis
@en
P2093
Mona Fouad
P2860
P304
P356
10.2217/FON.14.42
P407
P577
2014-10-01T00:00:00Z